Please assess the completion status of the following clinical trial:

Trial Title: Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \<33 and 0 days weeks gestational age at birth~2. ≥6 weeks and 0 days and ≤12 weeks and 0 days postnatal age at randomization~3. Remains hospitalized after birth (has never been discharged home)~4. Treating clinician deems infant eligible to receive 2-month vaccines~5. English- or Spanish-speaking parent(s)/legally authorized representative(s) (LAR(s))~6. Not planned for discharge within 60 hours of study entry~7. The parent/guardian must be willing and capable of providing permission for their child to participate through the written informed consent process~Exclusion Criteria:~1. Receipt of DTaP, IPV, PCV13, or Hib prior to enrollment. Previous administration of the first dose of HBV is permitted~2. Anticipated receipt of any vaccine other than DTaP, IPV, HBV, PCV13, or Hib during the first 60 hours after randomization~3. History of a severe allergic reaction (e.g. anaphylaxis) to a previous dose of any hepatitis B vaccine~4. History of a severe allergic reaction (e.g. anaphylaxis) to any component of the vaccines used in the study including neomycin, yeast and polymyxin B~5. History of latex allergy~6. Fever ≥38°C within 48 hours prior to randomization\*~   \*This may result in a temporary delay of randomization~7. Active known respiratory infection within 48 hours prior to randomization\*~   \*This may result in a temporary delay of randomization~8. Active infection being treated with systemic antimicrobials\*~   \*This may result in a temporary delay of randomization~9. Requiring mechanical ventilation or support with nasal intermittent positive pressure ventilation (NIPPV)\*~   \*This may result in a temporary delay of randomization~10. History of unstable progressive neurologic disorder of unknown cause~11. Known cause of apnea other than apnea of prematurity~12. Cyanotic heart disease (congenital or acquired)~13. Major invasive medical or surgical procedure (including circumcision) within 48 hours prior to randomization or anticipated to have major invasive medical or surgical procedure during the first 60 hours after randomization\*~    \*This may result in a temporary delay of randomization~14. Child or parent/LAR is an immediate relative of study staff or an employee who is supervised by study staff.~15. Any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccinated (Type: OTHER): In the study arm, infants will receive PCV13, DTaP, HBV, IPV, and Hib vaccines within 12 hours of randomization. Infants will be monitored from time of vaccination to 48 hours post-vaccination for the occurrence of apnea, bradycardia and desaturation.
- Unvaccinated (Type: NO_INTERVENTION): In the study arm, infants will not receive PCV13, DTaP, HBV, IPV, and Hib vaccines during the study. Infants will be monitored from randomization to 48 hours post-randomization for the occurrence of apnea, bradycardia and desaturation.

Based on this trial design, predict the completion outcome and termination type (if applicable).